Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalOphthalmologyDiabetic Macular EdemaTrial Update

Zhuochuming® Trial Evaluates 3+T&E vs 3+PRN in Diabetic Macular Edema

A clinical trial is underway to compare the efficacy of Zhuochuming® using a 3+T&E regimen against a 3+PRN regimen in treating treatment-naïve patients with diabetic macular edema.

Published: June 1, 2026
Updated: June 1, 2026
Author: Humanexa Intelligence
Therapeutic area: Ophthalmology / Diabetic Macular Edema
Asset: Ophthalmology
Trial SummaryCLN

Phase III

Ophthalmology / Diabetic Macular Edema

Status

Active

Signal Score

6.8

Signal assessment

Signal strength

moderate

Confidence level

moderate

Signalmoderate
Confidencemoderate

Why it matters

Portfolio teams should monitor this trial closely, as positive outcomes could enhance Zhuochuming®'s market positioning and inform future treatment guidelines.

Recommended action

Humanexa recommends Monitor.

Analysis

Key milestones include interim results on visual acuity and safety data at the 52-week mark.

Related companies & assets

Assets

  • Ophthalmology →
  • Diabetic Macular Edema →
  • Trial Update →

Sources & Humanexa intelligence

Source links

  • Zhuochuming® Trial Evaluates 3+T&E vs 3+PRN in Diabetic Macular Edema ↗

Related Humanexa pages

  • Zhuochuming® Trial Evaluates 3+T&E vs 3+PRN in Diabetic Macular Edema →

Related signals

Trial SummaryCLN

Phase III

Infectious Disease / T Cell Therapy

Status

Active

Signal Score

8.4

Clinicalhigh signal

Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise

A study is investigating the use of banked virus-specific T cells (VSTs) to treat persistent viral infections after allogeneic stem cell transplants.

August 2, 2026Read signal →
Trial SummaryCLN

Phase II

Oncology / Neuroendocrine Carcinomas

Status

Active

Signal Score

8.4

Clinicalhigh signal

Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas

A phase II/III trial is evaluating the efficacy of atezolizumab combined with standard chemotherapy in advanced or metastatic neuroendocrine carcinomas originating outside the lung.

August 1, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

  1. Home
  2. /Clinical
  3. /Zhuochuming® Trial Evaluates 3+T&E vs 3+PRN in Diabetic Macular Edema